New Hydrogen Nanocomplex Fights Drug-Resistant Kidney Cancer
- Authors
- Suxian Hu, Yan Zhu, Yi Duan, Liting Wang, Jian Yu, Zhihua Wu, Yourong Duan, Ying Sun
- Journal
- Materials Today Bio
- Year
- 2025
- DOI
- 10.1016/j.mtbio.2025.102450
- Study Type
- Cell Culture
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- China
- Health Condition
- Clear Cell Renal Cell Carcinoma
- Body System
- Urinary System
TL;DR
A hydrogen-generating nanocomplex co-delivering PT2385 and siRNA against lncARSR effectively reverses sunitinib resistance in clear cell renal cell carcinoma by inhibiting angiogenesis and enhancing mitochondrial apoptosis.
Key Finding
A hydrogen-based nanocomplex combining hydrogen gas, PT2385, and genetic silencing of lncARSR showed synergistic effects in reducing tumor blood vessel formation and promoting cancer cell death in sunitinib-resistant kidney cancer cells.
Summary
Researchers created a nanoparticle (tiny engineered particle) that delivers hydrogen gas, a cancer drug called PT2385, and genetic material to block a resistance-causing gene in kidney cancer cells that no longer respond to standard treatment. In laboratory tests with cancer cells, this combination reduced the growth of new blood vessels that feed tumors and triggered cancer cell death by damaging their mitochondria (the cell's energy centers).
Practical Takeaway
This is early laboratory research in cancer cells only, not human studies. While the results are promising for potentially overcoming drug resistance in kidney cancer, much more testing is needed before any clinical application. The study does not provide evidence about hydrogen water or other hydrogen products available to consumers.
Abstract (excerpt)
Hydrogen therapy has emerged as a promising agent for cancer treatment. Earlier research demonstrated that hydrogen (H2) possesses anti-angiogenic effects across multiple tumor types. However, no studies have yet investigated the anti-angiogenic effects of H2 in sunitinib-resistant clear cell renal…